SEK 0.60
+0.03 (+4.35%)
SEK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ACE.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional · 1 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney FunctionNCT04119843results2025-02-06Co-primary Endpoint: Lesion Border Delineation in Combined MRI Compared to Unenhanced MRIOpen-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Mangoral | Known or Suspected Focal Liver Lesions, Severe Renal Impairment | 87 | 2023-02-17actual | 2025-02-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19